Clinical Trial Update: EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 trial update for EPIC-ATTR evaluating eplontersen in transthyretin amyloid cardiomyopathy in Chinese subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: AstraZeneca | Conditions: Transthyretin Amyloid Cardiomyopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING